晚期卵巢上皮癌新辅助化疗的研究进展  

Research Progress of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer

作　　者：付清茹 齐红岩[1] 荣安娜 

机构地区：[1]内蒙古医科大学附属医院妇产科,呼和浩特010050

出　　处：《医学综述》2017年第5期891-895,共5页Medical Recapitulate

基　　金：内蒙古自治区科技计划项目(20130401);内蒙古自治区高等学校科学研究项目(NJZC13436)

摘　　要：卵巢癌在妇科恶性肿瘤中病死率居第1位,其中最常见的组织学类型是卵巢上皮癌。卵巢癌起病隐匿,疾病进展快,晚期卵巢上皮癌,恶性程度高,易复发。满意肿瘤细胞减灭术(OPCS)辅以术后铂类联合紫杉醇为基础的规范化疗是卵巢癌的传统治疗模式,而对于存在盆腹腔广泛转移,无法或预计无法达到OPCS的晚期卵巢上皮癌患者,新辅助化疗联合间歇性肿瘤细胞减灭术的治疗模式有望改善患者生活质量,提高生存期,是一种可选择的治疗策略。Ovarian cancer is the gynecological malignancy with the highest mortality rate,and one of the most common histological types is epithelial ovarian carcinoma. Ovarian cancer is featured with concealed onset, aggressive progression, and advanced epithelial ovarian cancer has a high level of malignancy, high rate of relapse. Optimal primary cytoreductive surgery（OPCS） combined with standard chemotherapy on the basis of platinum and paclitaxel is the traditional treatment of ovarian cancer. For patients with a wide range of pelvic and celiac transfer, which cannot be treated with 0PCS, neoadjuvant chemotherapy combined with interval debulking surgery is expected to improve patients＇ quality of life and extend survival, and is a kind of alternative treatment strategy.

关 键 词：晚期卵巢上皮性癌 新辅助化疗 肿瘤细胞减灭术 

分 类 号：R737.31[医药卫生—肿瘤]